Prevail Therapeutics Inc.
If you purchased Prevail Therapeutics Inc. securities and would like to join the action, please click "Join This Action" below.
PREVAIL MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF PREVAIL THERAPEUTICS INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – PRVL
December 15, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Prevail Therapeutics Inc. (NASDAQ: PRVL) to Eli Lilly and Company for $22.50 per share in cash plus one non-tradable contingent value right worth up to $4.00 per share in cash is fair to Prevail shareholders.
The investigation concerns whether Prevail and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for Prevail shareholders; (2) determine whether Eli Lilly is underpaying for Prevail; and (3) disclose all material information necessary for Prevail shareholders to adequately assess and value the merger consideration. On behalf of Prevail shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.